These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15814642)

  • 1. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
    Yonemori K; Ueno H; Okusaka T; Yamamoto N; Ikeda M; Saijo N; Yoshida T; Ishii H; Furuse J; Sugiyama E; Kim SR; Kikura-Hanajiri R; Hasegawa R; Saito Y; Ozawa S; Kaniwa N; Sawada J
    Clin Cancer Res; 2005 Apr; 11(7):2620-4. PubMed ID: 15814642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
    Sugiyama E; Kaniwa N; Kim SR; Kikura-Hanajiri R; Hasegawa R; Maekawa K; Saito Y; Ozawa S; Sawada J; Kamatani N; Furuse J; Ishii H; Yoshida T; Ueno H; Okusaka T; Saijo N
    J Clin Oncol; 2007 Jan; 25(1):32-42. PubMed ID: 17194903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
    Joerger M; Burgers JA; Baas P; Doodeman VD; Smits PH; Jansen RS; Vainchtein LD; Rosing H; Huitema AD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):25-33. PubMed ID: 21590444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
    Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
    Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
    Ludovini V; Floriani I; Pistola L; Minotti V; Meacci M; Chiari R; Garavaglia D; Tofanetti FR; Flacco A; Siggillino A; Baldelli E; Tonato M; Crinò L
    J Thorac Oncol; 2011 Dec; 6(12):2018-26. PubMed ID: 22052224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
    Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
    Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
    Ueno H; Kaniwa N; Okusaka T; Ikeda M; Morizane C; Kondo S; Sugiyama E; Kim SR; Hasegawa R; Saito Y; Yoshida T; Saijo N; Sawada J
    Br J Cancer; 2009 Mar; 100(6):870-3. PubMed ID: 19293806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
    Xu J; Zhou Y; Zhang J; Chen Y; Zhuang R; Liu T; Cai W
    Clin Chim Acta; 2012 Aug; 413(15-16):1284-7. PubMed ID: 22546611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
    Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
    Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
    Ding X; Chen W; Fan H; Zhu B
    Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
    Yoon KA; Woo SM; Hong EK; Jung MK; Park WS; Bae K; Han SS; Kim TH; Koh YH; Park SJ; Lee WJ
    Oncology; 2015; 89(6):345-50. PubMed ID: 26418006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
    Farrell JJ; Bae K; Wong J; Guha C; Dicker AP; Elsaleh H
    Pharmacogenomics J; 2012 Oct; 12(5):395-403. PubMed ID: 21625252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
    Sabbatini P; Aghajanian C; Leitao M; Venkatraman E; Anderson S; Dupont J; Dizon D; O'Flaherty C; Bloss J; Chi D; Spriggs D
    Clin Cancer Res; 2004 May; 10(9):2962-7. PubMed ID: 15131031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
    Li H; Wang X; Wang X
    Int J Biol Markers; 2014; 29(3):e224-32. PubMed ID: 24557790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
    Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
    PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
    Rademaker-Lakhai JM; Crul M; Pluim D; Sparidans RW; Baas P; Beijnen JH; van Zandwijk N; Schellens JH
    Anticancer Drugs; 2005 Oct; 16(9):1029-36. PubMed ID: 16162981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
    Li J; Xu D; Huang J; Wang YN; Ma XP; Lin ZY; Gong P
    Int J Biol Markers; 2019 Dec; 34(4):389-397. PubMed ID: 31603383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
    Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.